Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 3, Issue , 2016, Pages 27-34

  O'Bryant, Sid E ^a   Lista, Simone ^b   Rissman, Robert A ^c   Edwards, Melissa ^d   Zhang, Fan ^a   Hall, James ^a,e   Zetterberg, Henrik ^f,g   Lovestone, Simon ^h   Gupta, Veer ⁱ   Graff Radford, Neill ^j   Martins, Ralph ⁱ   Jeromin, Andreas ^k   Waring, Stephen ^l,m   Oh, Esther ⁿ   Kling, Mitchel ^o   Baker, Laura D ^p   Hampel, Harald ^b  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH TEXAS   (United States)

^e University of North Texas Health Science Center   (United States)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ EDITH COWAN UNIVERSITY   (Australia)

^j MAYO CLINIC   (United States)

^k QUANTERIX CORPORATION   (United States)

^l ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^m Texas Alzheimer's Research and Care Consortium   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Alzheimer's disease; Biomarker discovery; Blood; Diagnostics; Meso Scale Discovery; Multiplex assay platform; Plasma; Preanalytic processing; Proteins; Rules Based Medicine; Serum; Standardization

Indexed keywords

AMYLOID; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; EOTAXIN 3; FATTY ACID BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 5; INTERLEUKIN 6; PANCREAS POLYPEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR 1;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONTROLLED STUDY; ELECTROCHEMILUMINESCENCE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; PLASMA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEOMICS; SERUM;

EID: 84959378033     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.12.003     Document Type: Article

References (30)

1. Loannidis J.P. Why most published research findings are false. PLoS Med 2005, 2:e124.
2. Collins F.S., Tabak L.A. NIH plans to enhance reproducibility. Nature 2014, 505:612-613.
3. Unreliable research: Trouble at the lab 2013, 26-30. Economist The, The Economist, New York.
4. Prinz F., Schlange T., Asadullah K. Believe it or not: How much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10:712-713.
5. Henriksen K., O'Bryant S.E., Hampel H., Trojanowski J.Q., Montine T.J., Jeromin A., et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014, 10:115-131.
6. Snyder H.M., Carrillo M.C., Grodstein F., Henriksen K., Jeromin A., Lovestone S., et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014, 10:109-114.
7. O'Bryant S.E., Gupta V., Henriksen K., Edwards M., Jeromin A., Lista S., et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease. Alzheimers Dement 2015, 11:549-560.
8. Narayanan S. Effect of anticoagulants used for blood collection on laboratory tests. Proc JCLA 1993, 7:1-10.
9. Weber M., Rabenau B., Stanisch M., Nef H.M., Mollmann H., Elsasser A., et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res 2007, 120:811-814.
10. Watt A.D., Perez K.A., Rembach A.R., Masters C.L., Villemagne V.L., Barnham K.J. Variability in blood-based amyloid-β assays: The need for consensus on pre-analytical processing. J Alzheimers Dis 2012, 30:323-336.
11. Lista S., Faltraco F., Prvulovic D., Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 2013, 101-102:1-17.
12. Lista S., Faltraco F., Hampel H. Biological and methodological challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 2013, 101-102:18-34.
13. Hu W.T., Holtzman D.M., Fagan A.M., Shaw L.M., Perrin R., Arnold S.E., et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79:897-905.
14. O'Bryant S.E., Xiao G., Barber R., Reisch J., Doody R., Fairchild T., et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010, 67:1077-1081.
15. O'Bryant S.E., Xiao G., Edwards M., Devous M., Gupta V.B., Martins R., et al. Biomarkers of Alzheimer's disease among Mexican Americans. J Alzheimers Dis 2013, 34:841-849.
16. Doecke J., Laws S.M., Faux N.G., Wilson W., Burnham S.C., Lam C.P., et al. Blood-based protein biomarkers for the diagnosis of Alzheimer's disease. Arch Neurol 2012, 69:1318-1325.
17. Huebinger R., Xiao G., Wilhelmsen K.C., Diaz-Arrastia R., Zhang F., O'Bryant S.E., et al. Comparison of protein concentrations in serum versus plasma from Alzheimer's patients. Adv Alzheimers Dis 2012, 1:51-58.
18. O'Bryant S.E., Xiao G., Barber R., Huebinger R., Wilhelmsen K., Edwards M., et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS ONE 2011, 6:e28092.
19. O'Bryant S.E., Xiao G., Zhang F., Edwards M., German D.C., Yin X., et al. Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis 2014, 42:1325-1335.
20. Sattlecker M., Kiddle S.J., Newhouse S., Proitsi P., Nelson S., Williams S., et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 2014, 10:724-734.
21. Thambisetty M., An Y., Kinsey A., Koka D., Saleem M., Guntert A., et al. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage 2012, 59:212-217.
22. Soares H.D., Chen Y., Sabbagh M., Roher A., Schrijvers E., Breteler M. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci 2009, 1180:56-67.
23. McKhann D., Drockman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group. Neurology 1984, 34:939-944.
24. Bjerke M., Portelius E., Minthon L., Wallin A., Anckarsater H., Anckarsater R., et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 2010.
25. Kuhle J., Regeniter A., Leppert D., Mehling M., Kappos L., Lindberg R.L., et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010, 220:114-119.
26. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007, 13:1359-1362.
27. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
28. Killick R., Ribe E.M., Al-Shawi R., Malik B., Hooper C., Fernandes C., et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry 2014, 19:88-98.
29. O'Bryant S., Xiao G., Barber R., Riesch J., Hall J., Cullum C.M., et al. A blood based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 2011, 32:55-62.
30. O'Bryant S.E., Johnson L., Edwards M., Soares H., Devous M.D., Ross S., et al. The link between C-reactive protein and Alzheimer's disease among Mexican Americans. J Alzheimers Dis 2013, 34:701-706.